Phase II Study of Induction Irinotecan + Cisplatin Chemotherapy Followed by Concurrent Irinotecan + Cisplatin Plus Twice-Daily Thoracic Radiotherapy.
10.4046/trd.2007.63.2.154
- Author:
Jeong Eun LEE
1
;
Hee Sun PARK
;
Sung Soo JUNG
;
Ju Ock KIM
;
Moon June CHO
;
Jin Hwan KIM
;
Choong Sik LEE
;
Sun Young KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Chungnam National University Hospital & Cancer Research Institute, Daejeon, Korea. sykim@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Cisplatin;
Irinotecan;
Limited-disease;
Small cell lung cancer;
3-week cycle;
Chemotherapy-naive;
Twice-daily thoracic radiotherapy;
Concurrent chemoradiotherapy
- MeSH:
Anemia;
Appointments and Schedules;
Chemoradiotherapy;
Cisplatin*;
Cranial Irradiation;
Diarrhea;
DNA Topoisomerases, Type I;
Drug Therapy*;
Esophagitis;
Febrile Neutropenia;
Follow-Up Studies;
Humans;
Lung Neoplasms;
Neutropenia;
Radiotherapy*;
Small Cell Lung Carcinoma;
Survival Rate;
Thrombocytopenia;
Tomography, X-Ray Computed
- From:Tuberculosis and Respiratory Diseases
2007;63(2):154-164
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against small-cell lung cancer. Irinotecan also can act as a potential radiation sensitizer along with cisplatin. To evaluate efficacy and toxicity of irinotecan plus cisplatin (IP) with concurrent thoracic radiotherapy, we conducted a phase II study of IP followed by concurrent IP plus hyperfractionated thoracic radiotherapy in patients with previously untreated limited-stage small-cell lung cancer. METHODS: Twenty-four patients with previously untreated small-cell lung cancer were enrolled onto the study since November 2004. Irinotecan 60 mg/m2 was administered intravenously on days 1 and 8 in combination with cisplatin 60 mg/m2 on day1 every 21 days. From the first day of third cycle, twice-daily thoracic irradiation (total 45 Gy) was given. Prophylactic cranial irradiation was given to the patients who showed complete remission after concurrent chemoradiotherapy. Restaging was done after second and sixth cycle with chest CT and/or bronchosocpy. RESULTS: Up to November 2004, 19 patients were assessable. The median follow-up time was 12.5 months. A total of 99 cycles (median 5.2 cycles per patient) were administered. The actual dose intensity values were cisplatin 19.6 mg/m2/week and irinotecan 38.2 mg/m2/week. Among the 19 patients, the objective response rate was 95% (19 patients), with 9 patients (47%) having a complete response (CR). The major grade 3/4 hematological toxicities were neutropenia (35% of cycles), anemia (7% of cycles), thrombocytopenia (7% of cycles). Febrile neutropenia was 4% of cycles. The predominant grade 3/4 non-hematological toxicities was diarrhea (5% of cycles). Toxicities was not significantly different with concurrent administration of irinotecan and cisplatin with radiotherapy, except grade 3/4 radiation esophagitis (10% of patients). No treatment-related deaths were observed. The 1-year and 2-year survival rate of eligible patients was 89% (16/18) and 47% (9/18), respectively. CONCLUSION: Three-week schedule of irinotecan plus cisplatin followed by concurrent IP plus hyperfractionated thoracic radiotherapy is an effective treatment for limited disease small-cell lung cancer, with acceptable toxicity.
